Sweeping DEA Operation Targets Pharmacy Burglaries and the Illegal Sale of Addictive Prescription Medications
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Domestic Divisions
      • Foreign Divisions
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Forensic Sciences
      • GUARDS
      • Forensic Sciences Policy
      • Forensic Science Organizations
      • Forensic Science Contact
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
    • Education and Prevention
      • Family Summit
      • Red Ribbon
      • Kiki and the History of Red Ribbon Week
      • Red Ribbon Toolkit - Resources For Your Community
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Senior Citizens
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
      • Operation Warfighter
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Sweeping DEA Operation Targets Pharmacy Burglaries and the Illegal Sale of Addictive Prescription Medications

Sweeping DEA Operation Targets Pharmacy Burglaries and the Illegal Sale of Addictive Prescription Medications

August 29, 2024
|
Share Article
|
Download Press Release
For Immediate Release
Contact: DEA Public Affairs
Phone Number: (202) 307-7977

Ending the Diversion and Illegal Sale of Controlled Substances Remains a Top Priority for DEA

WASHINGTON – The U.S. Drug Enforcement Administration has seen an increase in burglaries at independent pharmacies across the country. Nearly 900 burglaries involving the theft of controlled substances were reported to DEA in 2023. Stolen prescription medications adversely impact these small businesses while also putting patients and the community at risk.

Earlier today in the Eastern District of Arkansas, representatives from DEA joined the U.S. Attorney’s Office to announce the results of a 21-month investigation into a Houston-based drug trafficking organization (DTO) responsible for hundreds of pharmacy burglaries across the country.

The culmination of this investigation led to the arrest of an additional 24 members of the DTO last month in Houston, bringing the total number of people facing charges connected to this drug ring to 42. The results of the first phase of this operation were announced in December. 

DEA’s Little Rock District Office led the investigation after identifying a string of pharmacy burglaries and thefts of pharmaceutical medications throughout Arkansas. With the assistance of DEA’s Special Operations Division, this organization has been linked to more than 200 pharmacy burglaries across the United States, including Alabama, Arkansas, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Mississippi, Missouri, Nebraska, Nevada, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, and Wyoming. 

Oxycodone, hydrocodone, alprazolam, and promethazine with codeine cough syrup were among the most common controlled substances stolen and transported to Houston to be sold illegally.

"From November 2023 to July 2024, the DEA, with our law enforcement partners, took down 42 individuals behind nearly 200 pharmacy burglaries in 31 states. This Houston-based network targeted rural pharmacies, stealing powerful drugs like Oxycodone, Xanax, and Adderall to flood the streets," said Administrator Anne Milgram. "These criminals even crawled on floors to dodge security, but they couldn't escape us. We dismantled their entire operation-street dealers, burglars, and all. In the fight against the opioid epidemic, the DEA is relentless in shutting down those who profit from fueling addiction."

In addition to today’s announcement, DEA has released a safety alert video and additional resources to help protect against pharmacy burglaries.   

This operation is part of an Organized Crime Drug Enforcement Task Forces (OCDETF) operation. OCDETF identifies, disrupts, and dismantles the highest-level criminal organizations that threaten the United States using a prosecutor-led, intelligence-driven, multi-agency approach. Additional information about the OCDETF Program can be found at https://www.justice.gov/OCDETF.

Preventing the Diversion of Controlled Substances

DEA is responsible for preventing, detecting, and investigating the diversion of controlled substances and listed chemicals, as well as regulating the nearly two million DEA registrants that manufacture, distribute, import or export controlled substances. Under the authority of the controlled substances laws and regulations of the United States, DEA uses a range of tools, including both criminal and administrative penalties, to protect our communities from the harms of illegally distributed controlled substances. 

Recent notable actions against DEA registrants to ensure the safety and health of Americans include:

  • Earlier this month, charges were announced against two doctors, Dr. Salvador Plasencia and Dr. Mark Chavez, and three others in connection to the death of actor Matthew Perry.  Dr. Plasencia is charged with seven counts of distribution of ketamine and two counts of altering and falsifying documents or records related to a federal investigation. Dr. Chavez has agreed to plead guilty to one count of conspiracy to distribute ketamine. At the time of the announcement DEA Administrator Anne Milgram said, “Matthew Perry’s journey began with unscrupulous doctors who abused their position of trust because they saw him as a payday, to street dealers who gave him ketamine in unmarked vials.” 
     
  • In July 2024, Rite Aid Corporation agreed to a settlement following DEA’s claims that it knowingly dispensed hundreds of thousands of unlawful prescriptions for controlled substances, including excessive quantities of opioids.
     
  • In June 2024, Ruthia He, the founder and CEO of DONE Global, Inc., and David Brody, the clinical president of DONE Health,  were arrested on charges of allegedly operating an online telehealth website that distributed Adderall and other stimulants in exchange for a monthly subscription fee. At the time of the arrests, Administrator Milgram said, “Diversion of Adderall and other prescription stimulants pills to persons who have no medical need only exacerbates the [stimulant] shortage and hurts any American with a legitimate medical need for the drug.” Several associates of DONE are also facing charges for their alleged participation in the scheme. 
     
  • In February 2024, DEA announced a settlement with pharmaceutical distributor Morris & Dickson Co., LLC, for failing to maintain effective controls against drug diversion and for failing to report thousands of suspicious orders for oxycodone and hydrocodone. 
     
  • In October 2023, DEA announced Operation Bottleneck, which resulted in administrative actions against six DEA-registered companies. Collectively, the companies failed to account for more than a million doses of opioids. “These companies have a legal obligation to account for every dose and every pill to protect the safety and health of the American people,” Administrator Milgram said in a statement.
     
  • In December 2022, DEA served an Order to Show Cause on Truepill, a retail pharmacy alleged to have wrongfully filled thousands of prescriptions for stimulants used in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Last year, DEA announced it reached a settlement agreement with Truepill after the company accepted responsibility for operating an unregistered online pharmacy. 
     
  • Since 2021, DEA has hosted Virtual Diversion Awareness Trainings (VDATs) available to all DEA-registered practitioners, including doctors, veterinarians, dentists, physician assistants, and nurse practitioners. The VDAT is designed to provide practitioners with important information, key resources, and tools to assist in the prevention of prescription drug diversion. To date, DEA has trained more than 45,000 registrants who attended the VDATs.
     
  • Since 2011, DEA has provided in-person and virtual drug diversion training opportunities to more than 32,000 pharmacists nationwide. These trainings help pharmacists identify signs of drug diversion and provide resources to help protect them from theft. In addition, DEA participates in and provides training for the National Association of Boards of Pharmacy and other national and state pharmacy associations. 
     
  • Since 2010, DEA’s National Prescription Drug Take Back Initiative has removed nearly 18.6 million pounds of unneeded prescription medications from communities. Removing unneeded medications from the home significantly reduces the opportunity for theft and misuse. DEA launched its newest diversion prevention campaign, Make Every Day Take Back Day, in December 2023 to encourage the use of the nearly 17,000 year-round disposal sites across the country.

 

In addition to these actions, DEA’s ongoing diversion prevention efforts include: 

For more information on DEA’s diversion prevention efforts and resources, visit: DEA Diversion Control Division (usdoj.gov).

 

# # #

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

@DEAHQ
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster